| Optimizing lonafarnib treatment for the management of chronic delta hepatitis: the LOWR HDV‐1 study C Yurdaydin, O Keskin, Ç Kalkan, F Karakaya, A Çalişkan, E Karatayli, ... Hepatology 67 (4), 1224-1236, 2018 | 157 | 2018 |
| Effect of Turkish propolis extracts on proteome of prostate cancer cell line Y Barlak, O Değer, M Çolak, SC Karataylı, AM Bozdayı, F Yücesan Proteome science 9, 1-11, 2011 | 109 | 2011 |
| Interferon treatment duration in patients with chronic delta hepatitis and its effect on the natural course of the disease C Yurdaydin, O Keskin, Ç Kalkan, F Karakaya, A Çalişkan, G Kabaçam, ... The Journal of infectious diseases 217 (8), 1184-1192, 2018 | 104 | 2018 |
| NOD2/CARD15, NOD1/CARD4, and ICAM-1 gene polymorphisms in Turkish patients with inflammatory bowel disease SC Özen, Ü Daǧlı, MY Kiliç, M Törüner, Y Çelik, M Özkan, I Soykan, ... Journal of gastroenterology 41, 304-310, 2006 | 72 | 2006 |
| Entecavir treatment of chronic hepatitis D G Kabaçam, FO Önder, M Yakut, G Seven, SC Karatayli, E Karatayli, ... Clinical infectious diseases 55 (5), 645-650, 2012 | 63 | 2012 |
| A phase 2 dose‐finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis C Yurdaydin, O Keskin, E Yurdcu, A Çalişkan, S Önem, F Karakaya, ... Hepatology 75 (6), 1551-1565, 2022 | 56 | 2022 |
| Cytokine gene polymorphisms in Turkish patients with inflammatory bowel disease Y Çelik, Ü Dagli, M Yalin Kiliç, M Törüner, S Ceren Özen, M Özkan, ... Scandinavian journal of gastroenterology 41 (5), 559-565, 2006 | 50 | 2006 |
| A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis—end of treatment results from the LOWR HDV-2 study C Yurdaydin, R Idilman, O Keskin, C Kalkan, MF Karakaya, A Caliskan, ... J Hepatol 66 (1), S33-S34, 2017 | 47 | 2017 |
| A one step real time PCR method for the quantification of hepatitis delta virus RNA using an external armored RNA standard and intrinsic internal control E Karataylı, YÇ Altunoğlu, SC Karataylı, SGK Alagöz, K Çınar, K Yalçın, ... Journal of clinical virology 60 (1), 11-15, 2014 | 41 | 2014 |
| Hepatitis C virus genotype distribution in Turkey remains unchanged after a decade: performance of phylogenetic analysis of the NS5B, E1, and 5’UTR regions in genotyping efficiency GK Alagoz, SC Karatayli, E Karatayli, E Çelik, O Keskin, B Dinç, K Cinar, ... Turk J Gastroenterol 25 (4), 405-410, 2014 | 34 | 2014 |
| Complete genome sequences and phylogenetic analysis of hepatitis delta viruses isolated from nine Turkish patients İ Çelik, E Karataylı, E Çevik, S Gökçe Kabakçı, SC Karataylı, B Dinç, ... Archives of virology 156, 2215-2220, 2011 | 30 | 2011 |
| Tumour necrosis factor‐alpha, interleukin‐10, interferon‐gamma and vitamin D receptor gene polymorphisms in patients with chronic hepatitis delta SC Karatayli, ZE Ulger, AA Ergul, O Keskin, E Karatayli, R Albayrak, ... Journal of viral hepatitis 21 (4), 297-304, 2014 | 29 | 2014 |
| Molecular characterization of a novel entecavir mutation pattern isolated from a multi-drug refractory patient with chronic hepatitis B infection E Karatayli, SC Karatayli, K Cinar, S Gokahmetoglu, K Güven, R Idilman, ... Journal of clinical virology 53 (2), 130-134, 2012 | 26 | 2012 |
| Efficacy of tenofovir in adefovir-experienced patients compared with treatment-naive patients with chronic hepatitis B O Keskin, AÇ Örmeci, B Baran, G Kabaçam, A Tüzün, E Karatayli, F Akyüz, ... Antiviral therapy 19 (6), 543-550, 2014 | 25 | 2014 |
| Subanalysis of the LOWR HDV-2 study reveals high response rates to Lonafarnib in patients with low viral loads C Yurdaydin, C Kalkan, F Karakaya, A Caliskan, S Karatayli, O Keskin, ... J Hepatol 68 (Suppl 1), S89, 2018 | 23 | 2018 |
| Serum connective tissue markers as predictors of advanced fibrosis in patients with chronic hepatitis B and D G Seven, SC Karatayli, SK Kose, M Yakut, G Kabacam, M Toruner, ... Turk J Gastroenterol 22 (3), 305-314, 2011 | 22 | 2011 |
| Interleukin‐28 gene polymorphisms may contribute to HB sAg persistence and the development of HB eAg‐negative chronic hepatitis B SC Karataylı, M Bozdayı, E Karataylı, T Öztürk, AA Husseini, R Albayrak, ... Liver International 35 (3), 846-853, 2015 | 21 | 2015 |
| Importance of serum SELDI-TOF-MS analysis in the diagnosis of early lung cancer C Şimşek, O Sonmez, A YURDAKUL, F Ózmen, N Zengin, A Keyf, ... Asian Pacific Journal of Cancer Prevention 14 (3), 2013 | 20 | 2013 |
| Clonal analysis of the quasispecies of antiviral-resistant HBV genomes in patients with entecavir resistance during rescue treatment and successful treatment of entecavir … E Karatayli, R Idilman, SC Karatayli, E Cevik, M Yakut, G Seven, ... Antiviral therapy 18 (1), 77-85, 2013 | 16 | 2013 |
| Discontinuation of lamivudine treatment in HBeAg-negative chronic hepatitis B: a pilot study with long-term follow-up F Karakaya, S Özer, Ç Kalkan, EA Tüzün, A Çalişkan, O Keskin, ... Antiviral Therapy 22 (7), 559-570, 2017 | 13 | 2017 |
A.Mithat BOZDAYIANKARA UNIVERSITY在 medicine.ankara.edu.tr 的电子邮件经过验证
